Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Summary
GBI Research, the leading business intelligence provider, has released its latest research “Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.
GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.
Scope
Summary
GBI Research, the leading business intelligence provider, has released its latest research “Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.
GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.
Scope
- Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 CNS DISORDER THERAPEUTIC MARKET TO 2017 - INTRODUCTION
2.1 GBI Research Report Guidance
3 CNS DISORDER THERAPEUTIC MARKET TO 2017 - GLOBAL MARKET OVERVIEW
3.1 Introduction
3.2 Revenue
3.2.1 Generic Share
3.2.2 Annual Cost of Treatment
3.3 Top CNS Drug Products
3.3.1 Seroquel (IR/XR) (quetiapine fumarate)
3.3.2 Zyprexa (olanzapine)
3.3.3 Cymbalta (duloxetine Hcl)
3.3.4 Copaxone (glatiramer acetate)
3.3.5 Lyrica (pregabalin)
3.3.6 Abilify (aripiprazole)
3.3.7 Avonex (Interferon beta-1a)
3.3.8 Rebif (interferon beta-1a)
3.3.9 Effexor (venlafaxine)
3.3.10 Betaferon /Betaseron (Interferon beta-1b)
4 CNS DISORDER THERAPEUTIC MARKET TO 2017 - GEOGRAPHICAL LANDSCAPE
4.1 Revenue Analysis by Geography
4.2 The US
4.2.1 Revenue
4.2.2 Annual Cost of Treatment
4.3 Top Five Countries of Europe
4.3.1 Revenue
4.3.2 Annual Cost of Treatment
4.4 Japan
4.4.1 Revenue
4.4.2 Annual Cost of Treatment
5 CNS DISORDER THERAPEUTIC MARKET TO 2017 - THERAPEUTIC LANDSCAPE
5.1 Alzheimer's Disease
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Treatment
5.1.4 Treatment Usage Patterns
5.2 Drivers and Restraints to Alzheimer's Disease Market
5.2.1 Drivers for Alzheimer's disease Market
5.2.2 Restraints for Alzheimer's disease Market
5.3 Attention Deficit Hyperactivity Disorder (ADHD)
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Treatment
5.3.4 Treatment Usage Patterns
5.4 Drivers and Barriers to ADHD Market
5.4.1 Drivers for ADHD Market
5.4.2 Barriers for ADHD Market
5.5 Bipolar Disorder
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Treatment
5.5.4 Treatment Usage Patterns
5.6 Drivers and Barriers to Bipolar Disorder Market
5.6.1 Drivers for Bipolar Disorder Market
5.6.2 Barriers for Bipolar Disorder Market
5.7 Diabetic Neuropathy
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Treatment
5.7.4 Treatment Usage Pattern
5.8 Drivers and Restraints to Diabetic Neuropathy Market
5.8.1 Drivers for Diabetic Neuropathy Market
5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market
5.9 Epilepsy
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Treatment
5.9.4 Treatment Usage Patterns
5.10 Drivers and Barriers to Epilepsy Market
5.10.1 Drivers for Epilepsy Market
5.10.2 Barriers to Epilepsy Market
5.11 Insomnia
5.11.1 Introduction
5.11.2 Revenue
5.11.3 Annual Cost of Treatment
5.11.4 Treatment Usage Patterns
5.12 Drivers and Barriers to Insomnia Market
5.12.1 Drivers for Insomnia Market
5.12.2 Barriers for Insomnia Market
5.13 Migraine
5.13.1 Introduction
5.13.2 Revenue
5.13.3 Annual Cost of Treatment
5.13.4 Treatment Usage Patterns
5.14 Drivers and Barriers for Migraine Market
5.14.1 Drivers for Migraine Market
5.14.2 Barriers for Migraine Market
5.15 Multiple Sclerosis
5.15.1 Introduction
5.15.2 Revenue
5.15.3 Annual Cost of Treatment
5.15.4 Treatment Usage Patterns
5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market
5.16.1 Drivers for Multiple Sclerosis Market
5.16.2 Restraints for Multiple Sclerosis Market
5.17 Parkinson’s Disease
5.17.1 Introduction
5.17.2 Revenue
5.17.3 Annual Cost of Treatment
5.17.4 Treatment Usage Patterns
5.18 Drivers and Restraints to Parkinson’s Disease Therapeutics Market
5.18.1 Drivers for the Parkinson’s disease Therapeutics Market
5.18.2 Restraints for the Parkinson’s disease Therapeutics Market
5.19 Schizophrenia
5.19.1 Introduction
5.19.2 Revenue
5.19.3 Annual Cost of Treatment
5.19.4 Treatment Usage Pattern
5.20 Drivers and Barriers to Schizophrenia Market
5.20.1 Drivers for Schizophrenia Market
5.20.2 Barriers for Schizophrenia Market
5.21 Major Depressive Disorder (MDD)
5.21.1 Introduction
5.21.2 Revenue
5.21.3 Annual Cost of Treatment
5.21.4 Treatment Usage Patterns
5.22 Drivers and Barriers to MDD Market
5.22.1 Drivers for MDD Market
5.22.2 Barriers for MDD Market
6 CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS MARKET TO 2017 - PRODUCT PIPELINE ANALYSIS
6.1 Introduction
6.1.1 Product Pipeline by Indication
6.1.2 Product Pipeline by Clinical Stage of Development
6.2 Alzheimer's disease
6.2.1 Introduction
6.3 Attention Deficit Hyperactivity Disorder (ADHD)
6.3.1 Introduction
6.4 Bipolar Disorder
6.4.1 Introduction
6.5 Diabetic Neuropathy
6.5.1 Introduction
6.6 Epilepsy
6.6.1 Introduction
6.7 Insomnia
6.7.1 Introduction
6.8 Major Depressive Disorder (MDD)
6.8.1 Introduction
6.9 Migraine
6.9.1 Introduction
6.10 Multiple Sclerosis
6.10.1 Introduction
6.11 Parkinson's Disease
6.11.1 Introduction
6.12 Schizophrenia
6.12.1 Introduction
6.13 NDA Filed Molecules
6.13.1 Alzheimer's disease
6.13.2 Bipolar Disorder
6.13.3 Epilepsy
6.13.4 Insomnia
6.13.5 MDD
6.13.6 Migraine
6.13.7 Parkinson’s disease
6.13.8 Multiple sclerosis
7 CNS DISORDER THERAPEUTIC MARKET TO 2017 - COMPETITIVE LANDSCAPE
7.1 Market Share Analysis
7.1.1 Eli Lilly
7.1.2 Pfizer
7.1.3 AstraZeneca
7.1.4 Johnson & Johnson (J&J)
7.1.5 Teva
8 CNS DISORDER THERAPEUTIC MARKET TO 2017 - M&A LANDSCAPE
8.1 M&A Deals (2010-2011)
8.1.1 M&A Deals by Region
8.1.2 M&A Deals by Indication
8.1.3 M&A Deals by Value
8.1.4 Deal Summary of M&A Deals by Value
8.2 Licensing Deals
8.2.1 Deal Summary
8.3 Co-development Deals
8.3.1 Deal Summary
9 CNS DISORDER THERAPEUTIC MARKET TO 2017 - APPENDIX
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Geographical Landscape
9.3.6 Pipeline Analysis
9.3.7 Competitive Landscape
9.3.8 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources 230
LIST OF TABLES
Table 1: CNS Disorder Therapeutic Market, Global, Revenue ($bn), 2002-2010
Table 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2010-2017
Table 3: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 5: CNS Disorder Therapeutic Market, The US, Revenue ($m), 2002-2010
Table 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast($m), 2010-2017
Table 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2010
Table 8: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2010-2017
Table 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue ($m), 2002-2010
Table 10: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017
Table 11: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
Table 12: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017
Table 13: CNS Disorder Therapeutic Market, Japan, Revenue ($m), 2002-2010
Table 14: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2010-2017
Table 15: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2010
Table 16: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2010-2017
Table 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010
Table 18: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010
Table 19: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2010-2017
Table 20: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010
Table 21: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017
Table 22: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010
Table 23: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2010-2017
Table 24: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010
Table 25: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017
Table 26: CNS Disorder Therapeutic Market, ADHD, Global Revenue ($m), 2002-2010
Table 27: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2010-2017
Table 28: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2010
Table 29: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2010-2017
Table 30: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2010
Table 31: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2010-2017
Table 32: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 33: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 34: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue ($m), 2002-2010
Table 35: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2010-2017
Table 36: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2010
Table 37: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2010-2017
Table 38: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010
Table 39: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017
Table 40: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 41: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 42: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010
Table 43: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast($m), 2010-2017
Table 44: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010
Table 45: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017
Table 46: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010
Table 47: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017
Table 48: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010
Table 49: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017
Table 50: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue ($m), 2002-2010
Table 51: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2010-2017
Table 52: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2002-2010
Table 53: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2010-2017
Table 54: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2010
Table 55: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2010-2017
Table 56: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 57: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 58: CNS Disorder Therapeutic Market, Insomnia, Global Revenue ($m), 2002-2010
Table 59: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast($m), 2010-2017
Table 60: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2010
Table 61: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2010-2017
Table 62: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2010
Table 63: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2010-2017
Table 64: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 65: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 66: CNS Disorder Therapeutic Market, Migraine, Global Revenue ($m), 2002-2010
Table 67: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast($m), 2010-2017
Table 68: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2002–2010
Table 69: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2010–2017
Table 70: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2010
Table 71: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2010-2017
Table 72: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 73: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 74: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010
Table 75: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2010-2017
Table 76: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010
Table 77: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017
Table 78: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010
Table 79: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017
Table 80: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010
Table 81: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017
Table 82: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Revenue ($m), 2002-2010
Table 83: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Revenue Forecast ($m), 2010-2017
Table 84: CNS Disorder Therapeutic Market, Parkinson’s Disease, Revenue by Country ($m), 2002-2010
Table 85: CNS Disorder Therapeutic Market, Parkinson’s Disease, Revenue by Country ($m), 2010-2017
Table 86: CNS Disorder Therapeutic Market, Parkinson’s Disease, Annual Cost of Treatment ($), 2002-2010
Table 87: CNS Disorder Therapeutic Market, Parkinson’s Disease, Annual Cost of Treatment ($), 2010-2017
Table 88: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Treatment Usage Pattern (Thousand), 2002-2010
Table 89: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Treatment Usage Pattern (Thousand), 2010-2017
Table 90: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue ($m), 2002-2010
Table 91: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2010-2017
Table 92: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2010
Table 93: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2010-2017
Table 94: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010
Table 95: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017
Table 96: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2010
Table 97: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2010-2017
Table 98: CNS Disorder Therapeutic Market, MDD, Global Revenue ($m), 2002-2010
Table 99: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast ($m), 2010-2017
Table 100: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2010
Table 101: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2010-2017
Table 102: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2010
Table 103: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2010-2017
Table 104: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2002-2010
Table 105: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2010-2017
Table 106: CNS Disorder Therapeutic Market, Alzheimer's Disease, Discovery Product Pipeline, 2011
Table 107: CNS Disorder Therapeutic Market, ADHD Product Pipeline, 2011
Table 108: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline, 2011
Table 109: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline, 2011
Table 110: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline, 2011
Table 111: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline, 2011
Table 112: CNS Disorder Therapeutic Market, MDD, Product Pipeline, 2011
Table 113: CNS Disorder Therapeutic Market, Migraine, Product Pipeline, 2011
Table 114: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline, 2011
Table 115: CNS Disorder Therapeutic Market, Parkinson’s Disease, Product Pipeline, 2011
Table 116: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline, 2011
Table 117: CNS Disorder Therapeutic Market, Global, M&A Deals ($m), 2010-2011
Table 118: CNS Disorder Therapeutic Market, Global, Announced M&A Deals ($m), 2010-2011
Table 119: CNS Disorder Therapeutic Market, Global, Licensing Deals ($m), 2010-2011
Table 120: CNS Disorder Therapeutic Market, Co-developments, 2010-2011 218
LIST OF FIGURES
Figure 1: CNS Disorder Therapeutic Market, Global, Revenue Share by Indication (%), 2010
Figure 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017
Figure 3: CNS Disorder Therapeutic Market, Global, Generic Share (%), 2010 and 2017
Figure 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 5: CNS Disorder Therapeutic Market, Revenue by Geography (%),2010
Figure 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast ($m), 2002-2017
Figure 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2017
Figure 8: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017
Figure 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017
Figure 10: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2002-2017
Figure 11: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2017
Figure 12: CNS Disorder Therapeutic Market, Alzheimer's Disease Treatment Algorithm
Figure 13: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2002-2017
Figure 14: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2017
Figure 15: CNS Disorder Therapeutic Market, Alzheimer's Disease, Generic Share in Alzheimer’s Disease Market, 2010 and 2017
Figure 16: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2017
Figure 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 18:CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Market Drivers and Restraints, 2010-2017
Figure 19: CNS Disorder Therapeutic Market, ADHD Treatment Algorithm
Figure 20: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2002-2017
Figure 21: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2017
Figure 22: CNS Disorder Therapeutic Market, ADHD, Generic Share in ADHD Market, 2010 and 2017
Figure 23: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2017
Figure 24: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2017
Figure 25: CNS Disorder Therapeutic Market, ADHD, Global Market Drivers and Barriers, 2010-2017
Figure 26: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm
Figure 27: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2002-2017
Figure 28: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2017
Figure 29: CNS Disorder Therapeutic Market, Bipolar Disorder, Generic Share in Bipolar Disorder Market, 2010 and 2017
Figure 30: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017
Figure 31: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2017
Figure 32: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017
Figure 33: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm
Figure 34: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast ($m), 2002-2017
Figure 35: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017
Figure 36: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market ($m), 2010 and 2017
Figure 37: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017
Figure 38: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 39: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017
Figure 40: CNS Disorder Therapeutic Market, Epilepsy, Treatment Algorithm
Figure 41: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2002-2017
Figure 42: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m),2002-2017
Figure 43: CNS Disorder Therapeutic Market, Epilepsy, Generic Share in Epilepsy Market, 2010 and 2017
Figure 44: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2017
Figure 45: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2017
Figure 46: CNS Disorder Therapeutic Market, Epilepsy, Global Market Drivers and Barriers, 2010-2017
Figure 47: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm
Figure 48: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast ($m), 2002-2017
Figure 49: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2017
Figure 50: CNS Disorder Therapeutic Market, Insomnia, Generic Share in Insomnia Market, 2010 and 2017
Figure 51: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2017
Figure 52: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2017
Figure 53: CNS Disorder Therapeutic Market, Insomnia, Global Market Drivers and Barriers, 2010-2017
Figure 54: CNS Disorder Therapeutic Market, Migraine, Treatment Algorithm
Figure 55: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast ($m), 2002-2017
Figure 56: CNS Disorder Therapeutic Market, Mirgaine, Revenue by Country ($m), 2002-2017
Figure 57: CNS Disorder Therapeutic Market, Migraine, Generic Share in Migraine Market, 2010 and 2017
Figure 58: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2017
Figure 59: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2017
Figure 60: CNS Disorder Therapeutic Market, Migraine, Global Market Drivers and Barriers, 2010-2017
Figure 61: CNS Disorder Therapeutic Market, Multiple Sclerosis (RRMS), Treatment Algorithm
Figure 62:CNS Disorder Therapeutic Market, Multiple Sclerosis (PRMS), Treatment Algorithm
Figure 63: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2002-217
Figure 64: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017
Figure 65: CNS Disorder Therapeutic Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, 2010 and 2017
Figure 66: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017
Figure 67: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 68: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017
Figure 69: CNS Disorder Therapeutic Market, Parkinson’s Disease, Treatment Algorithm
Figure 70: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Revenue Forecast($m), 2002-2017
Figure 71: CNS Disorder Therapeutic Market, Parkinson’s Disease, Revenue by Country ($m), 2002-2017
Figure 72: CNS Disorder Therapeutic Market, Parkinson’s Disease, Generic Share in Parkinson’s Disease Market ($m), 2010 and 2017
Figure 73: CNS Disorder Therapeutic Market, Parkinson’s Disease, Annual Cost of Treatment ($), 2002-2017
Figure 74: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 75: CNS Disorder Therapeutic Market, Parkinson’s Disease, Global Market Drivers and Restraints, 2010-2017
Figure 76: CNS Disorder Therapeutic Market, Schizophrenia, Treatment Algorithm
Figure 77: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2002-2017
Figure 78: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2017
Figure 79: CNS Disorder Therapeutic Market, Schizophrenia, Generic Share in Schizophrenia Market, 2010 and 2017
Figure 80: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010
Figure 81: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 82: CNS Disorder Therapeutic Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017
Figure 83: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm
Figure 84: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast($m), 2002-2017
Figure 85: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2017
Figure 86: CNS Disorder Therapeutic Market, MDD, Generic Share in MDD Market, 2010 and 2017
Figure 87: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2017
Figure 88: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Pattern (Thousand), 2002-2017
Figure 89: CNS Disorder Therapeutic Market, MDD, Global Market Drivers and Barriers, 2010-2017
Figure 90: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Indication (%),2011
Figure 91: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Clinical Stage of Development (%),2011
Figure 92: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline (%),2011
Figure 93: CNS Disorder Therapeutic Market, ADHD, Product Pipeline (%), 2011
Figure 94: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline (%),2011
Figure 95: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline (%),2011
Figure 96: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline (%),2011
Figure 97: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline (%), 2011
Figure 98: CNS Disorder Therapeutic Market, MDD, Product Pipeline (%),2011
Figure 99: CNS Disorder Therapeutic Market, Migraine, Product Pipeline (%), 2011
Figure 100: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline (%), 2011
Figure 101: CNS Disorder Therapeutic Market, Parkinson’s Disease, Product Pipeline (%), 2011
Figure 102: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline (%), 2011
Figure 103: CNS Disorder Therapeutic Market, Global Top Companies Share (%), 2010
Figure 104: CNS Disorder Therapeutic Market, SWOT Analysis of Eli Lilly, 2010
Figure 105: CNS Disorder Therapeutic Market, SWOT Analysis of Pfizer, 2010
Figure 106: CNS Disorder Therapeutic Market, SWOT Analysis of AstraZeneca, 2010
Figure 107: CNS Disorder Therapeutic Market, SWOT Analysis of Johnson & Johnson, 2010
Figure 108: CNS Disorder Therapeutic Market, SWOT Analysis of Teva
Figure 109: CNS Disorder Therapeutic Market, Global M&A Deals by Region, 2010-2011
Figure 110: CNS Disorder Therapeutic Market, Global M&A Deals by Indication, 2010-2011
Figure 111: CNS Disorder Therapeutic Market, Global, M&A Deals by Value ($m), 2010-2011
Figure 112: CNS Disorder Therapeutic Market, Licensing Deals, by Indication, 2010-2011
Figure 113: CNS Disorder Therapeutic Market, Co-developments by Indication, 2010-2011
Figure 114: GBI Research Market Forecasting Model 228
COMPANIES MENTIONED
Eli Lilly
Pfizer
AstraZeneca
Johnson & Johnson (J&J)
Teva Skip to top